Evidence map›Paper›PMID 29311110›Full record

ArticleThe Journal of pharmacology and experimental therapeutics2018

Long-Lasting In Vivo Effects of the Cannabinoid CB1 Antagonist AM6538.

Carol A Paronis, Girish R Chopda, Kiran Vemuri, Ani S Zakarian, Alexandros Makriyannis, Jack Bergman

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of pharmacology and experimental therapeutics, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.7field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 5 citations in OpenAlex.

  1. Probing the CBMolecular pharmacology · 2019
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Carol A ParonisCenter for Drug Discovery (C.A.P., K.V., A.M.) and Department of Pharmaceutical Sciences (C.A.P., G.R.C., A.M.), Northeastern University, Boston, Massachusetts; and Preclinical Pharmacology Program, McLean Hospital, Belmont, Massachusetts (C.A.P., A.S.Z., J.B.) cparonis@mclean.harvard.edu.
Girish R ChopdaCenter for Drug Discovery (C.A.P., K.V., A.M.) and Department of Pharmaceutical Sciences (C.A.P., G.R.C., A.M.), Northeastern University, Boston, Massachusetts; and Preclinical Pharmacology Program, McLean Hospital, Belmont, Massachusetts (C.A.P., A.S.Z., J.B.).
Kiran VemuriCenter for Drug Discovery (C.A.P., K.V., A.M.) and Department of Pharmaceutical Sciences (C.A.P., G.R.C., A.M.), Northeastern University, Boston, Massachusetts; and Preclinical Pharmacology Program, McLean Hospital, Belmont, Massachusetts (C.A.P., A.S.Z., J.B.).
Ani S ZakarianCenter for Drug Discovery (C.A.P., K.V., A.M.) and Department of Pharmaceutical Sciences (C.A.P., G.R.C., A.M.), Northeastern University, Boston, Massachusetts; and Preclinical Pharmacology Program, McLean Hospital, Belmont, Massachusetts (C.A.P., A.S.Z., J.B.).
Alexandros MakriyannisCenter for Drug Discovery (C.A.P., K.V., A.M.) and Department of Pharmaceutical Sciences (C.A.P., G.R.C., A.M.), Northeastern University, Boston, Massachusetts; and Preclinical Pharmacology Program, McLean Hospital, Belmont, Massachusetts (C.A.P., A.S.Z., J.B.).
Jack BergmanCenter for Drug Discovery (C.A.P., K.V., A.M.) and Department of Pharmaceutical Sciences (C.A.P., G.R.C., A.M.), Northeastern University, Boston, Massachusetts; and Preclinical Pharmacology Program, McLean Hospital, Belmont, Massachusetts (C.A.P., A.S.Z., J.B.).
McLean Hospital · USNortheastern University · US

Funding

Cannabinergic Medications for Methamphetamine AddictionR37DA023142 · NIDA · NORTHEASTERN UNIVERSITY · PI MAKRIYANNIS, ALEXANDROS · 2007 to 2016
$7.1M
Behavioral Pharmacology of Synthetic CannabinoidsR01DA043700 · NIDA · MCLEAN HOSPITAL · PI PARONIS, CAROL A · 2018 to 2022
$2.7M
Cannabinoid Dependence ResubmissionR21DA035411 · NIDA · MCLEAN HOSPITAL · PI PARONIS, CAROL A · 2014 to 2015
$432k
NIDA NIH HHS R01 DA043700NIDA NIH HHS R21 DA035411NIDA NIH HHS R37 DA023142
6 · The paper itself

Abstract

AM6538 is a cannabinoid antagonist that binds CB1 receptors expressed in HEK-293 cells in a wash-resistant manner. The effects of AM6538 in live animals has not previously been established. We characterized the antagonist effects of AM6538 in male mice, using a warm-water tail-withdrawal assay, and in male squirrel monkeys trained to discriminate the CB1 agonist AM4054 from vehicle. The cannabinoid agonists WIN 55,212, Δ

Indexed as

AnimalsBehavior, AnimalCannabinoid Receptor AntagonistsDrug InteractionsHumansKineticsMiceNitratesPiperidinesPyrazolesReceptor, Cannabinoid, CB1RimonabantAM6538Cannabinoid Receptor AntagonistsNitratesPiperidinesPyrazolesReceptor, Cannabinoid, CB1Rimonabant

Identifiers

PMID29311110
PMCPMC5803641
OpenAlexW2783420731

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.